Skip to main content
Akero Therapeutics, Inc. logo

Akero Therapeutics, Inc. — Investor Relations & Filings

Ticker · AKRO ISIN · US00973Y1082 LEI · 549300SI3KG74LBE2955 US Professional, scientific and technical activities
Open in API
Filings indexed 719 across all filing types
Latest filing 2021-12-10 Board/Management Inform…
Country US United States of America
Listing US AKRO

About Akero Therapeutics, Inc.

https://akerotx.com/

Akero Therapeutics, Inc. is a clinical-stage company focused on developing and commercializing transformational treatments for patients with serious metabolic diseases characterized by high unmet medical need. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21 (FGF21). EFX is being evaluated in multiple clinical trials as a potential foundational therapy for metabolic dysfunction-associated steatohepatitis (MASH), a severe form of liver disease. The program aims to provide a differentiated treatment that addresses the complex pathophysiology of MASH by restoring metabolic balance.

Recent filings

Filing Released Lang Actions
FORM 8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce significant events. The key content is the departure of a director, Kevin Bitterman, from the company's board effective December 31, 2021. This matches the description of announcements related to changes in the company's board of directors or senior management. The document length is 3272 characters, which is relatively short and focused on management changes. Therefore, the appropriate classification is Board/Management Information (MANG).
2021-12-10 English
OWNERSHIP DOCUMENT
Director's Dealing
2021-12-03 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce significant events or disclosures by a company. The text includes references to a press release about clinical study data and a presentation at a medical meeting, but it does not contain comprehensive financial statements or detailed financial analysis. It also explicitly states that the press release is furnished as an exhibit and is not "filed" for certain regulatory purposes. The document is not an Annual Report, Interim Report, Earnings Release, or any other detailed financial report. Instead, it is a regulatory filing announcing specific events and disclosures. Therefore, the appropriate classification is Regulatory Filings (RNS). The document length (7593 characters) and content support this classification with high confidence.
2021-11-12 English
10-Q
Interim / Quarterly Report Q3 2021
2021-11-12 English
FORM 8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated November 12, 2021, reporting the financial results for the quarter ended September 30, 2021. It references a press release (Exhibit 99.1) containing the financial results. The document itself is short (3761 characters) and primarily serves as a current report announcing the earnings release rather than containing detailed financial statements or analysis. According to the rules, initial announcements of quarterly financial results are classified as Earnings Release (ER).
2021-11-12 English
OWNERSHIP DOCUMENT
Director's Dealing
2021-11-05 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.